ClinicalTrials.gg
RecruitingNCT07283263Updated Jan 7, 2026

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.

A Phase 1 interventional study of BMS-985521 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on BMS-986521 exposure.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • Pharmacokinetics
  • BMS-986521
  • Placebo
  • Drug-food Interaction
  • Single Ascending Dose (SAD)
  • Multiple Ascending Dose (MAD)
  • Elderly
  • Relative Bioavailability
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy males and females (assigned at birth) who are not of , with no abnormalities in medical history, physical exam, , or lab tests.
  • Participants must have a (BMI) between 18 and 32 kg/m² (inclusive) and body weight of at least 50 kg.
  • For Part B/Cohort 11 only: participants with stable cardiovascular conditions may be included if deemed suitable by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have any significant medical condition or history (renal, hepatic, hematologic, GI, endocrine, pulmonary, neurologic, or immunologic) that may affect drug absorption, distribution, metabolism, or excretion (ADME), or pose a risk to the participant.
  • Participants must not have a history of rhabdomyolysis, cancer (except certain cured skin or cervical cancers), hematologic , or myelodysplastic syndrome.
  • Participants must not have recent or current significant GI disease, major surgery, or medical interventions affecting ADME (except appendectomy or cholecystectomy).
  • Participants must not have had a blood transfusion within 4 weeks or have an inability to tolerate oral medication or venous access.
  • Other protocol defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    Part A Cohort 1

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part A Cohort 2

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part A Cohort 3

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part A Cohort 4

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part A Cohort 5

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part A Cohort 6

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part B Cohort 7

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part B Cohort 8

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part B Cohort 9

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part B Cohort 10

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part B Cohort 11

    Drug: BMS-985521 · Other: Placebo

  • Experimental
    Part C

    Drug: BMS-985521

Interventions

  • DrugBMS-985521

    Specified dose on specified days.

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (AEs)

    Time frame: Up to approximately Day 40

  2. Number of participants with treatment-emergent serious adverse events (SAEs)

    Time frame: Up to approximately Day 40

  3. Number of participants with Treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately Day 14

Secondary outcomes

  1. Maximum Concentration (Cmax) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  2. Time to Cmax (Tmax) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  3. Area Under the Concentration-Time Curve from Time Zero to the Last Measured Time Point (AUC(0-T)) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  4. Area Under the Concentration-Time Curve from Time Zero to 24 Hours (AUC(0-24)) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  5. Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC(INF)) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  6. Concentration Over a Dosing Interval (tau) (AUC(TAU)) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  7. Elimination Half-Life (T-HALF) of BMS-986521 in Plasma

    Time frame: Up to approximately Day 14

  8. Apparent Clearance of BMS-986521 from Plasma after Dosing (CLT/F)

    Time frame: Up to approximately Day 14

  9. Apparent Volume of Distribution in Plasma after Dosing (Vz/F) of BMS-986521

    Time frame: Up to approximately Day 14

  10. Accumulation Index Based on Maximum Concentration (Cmax) in Plasma after Multiple Dosing (AI_Cmax) of BMS-986521

    Time frame: Up to approximately Day 14

  11. Accumulation Index Based on Area Under the Curve (AUC) in Plasma After Multiple Dosing (AI_AUC) of BMS-986521

    Time frame: Up to approximately Day 14

  12. Geometric Mean Cmax BMS-986521 under fed and fasted conditions

    Cohort 3

    Time frame: Up to approximately Day 11

  13. Geometric Mean AUC(0-T) BMS-986521 under fed and fasted conditions

    Cohort 3

    Time frame: Up to approximately Day 11

  14. Geometric Mean AUC(INF) BMS-986521 under fed and fasted conditions

    Cohort 3

    Time frame: Up to approximately Day 11

  15. Geometric mean ratios of Cmax for BMS-986521 oral tablet vs solution

    Part C

    Time frame: Up to approximately Day 11

  16. Geometric mean ratios of AUC(0-T) for BMS-986521 oral tablet vs solution

    Part C

    Time frame: Up to approximately Day 11

  17. Geometric mean ratios of AUC(INF) for BMS-986521 oral tablet vs solution

    Part C

    Time frame: Up to approximately Day 11

07

Study locations

1 of 1 sites recruiting
  • CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
    Anaheim, California 92801, United States
    Recruiting
    • Peter Winkle, Site 0001 · Contact949-295-7809
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 15, 2025
StartActual
Dec 23, 2025
Primary completionEst.
Nov 17, 2026
CompletionEst.
Nov 17, 2026
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07283263
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 23, 2025
Primary completion
Nov 17, 2026 (estimated)
Completion
Nov 17, 2026 (estimated)
Last update
Jan 7, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain the NCT# and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion